Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
X4 Pharmaceuticals Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 3 distinct examiners and 3 distinct art units, so the pending work is distributed across separate examination assignments. RAO, SAVITHA M is the busiest examiner, with 1 pending action.
The matching counts for pending actions, examiners, and art units indicate that each action is associated with a separate examiner and technical unit. Prosecution planning should therefore be coordinated across the matters while preserving application-specific responses. The RAO file may provide a useful reference for monitoring examiner correspondence, but the data does not show concentration beyond that single action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| JAVANMARD, SAHAR | 1 | 65.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18895123 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | RAO, SAVITHA M | — |
| 18465823 | CXCR4 INHIBITORS AND USES THEREOF | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18895123 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | RAO, SAVITHA M | 1691 | DP | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18828839 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | SEAMAN, D MARGARET M | 1625 | DP | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18465823 | CXCR4 INHIBITORS AND USES THEREOF | JAVANMARD, SAHAR | 1622 | §112Other | Non-Final OA | — | Pending | Sep 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialX4 Pharmaceuticals Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Savitha M Rao has the most, with 1 of X4 Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.